Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Study of Different Doses of Ripertamab in Children With Frequent Relapses or Steroid-Dependent Nephrotic Syndrome
NCT07388810Not yet recruiting
- Start
- Feb 2026
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Randomised, open-label trial of ripertamab in nephrotic syndrome (2 arms). Primary endpoint: Relapse free survival rate at 1 year. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
ripertamab
03
Conditions
nephrotic syndrome
Beyond the preview
Go deeper on NCT07388810.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07388810.